CliffBio
small molecule

BORTEZOMIB

BORTEZOMIB

Loss of exclusivity—loss of exclusivity
CompanyShilpa Medicare →See this company's full patent-cliff portfolio

Drug detail

Brand nameBORTEZOMIB
Active ingredientBORTEZOMIB
Strength3.5MG/1.4ML (2.5MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalAugust 2024
Marketing statusRX

More from Shilpa Medicare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

BORTEZOMIB patent cliff — loss of exclusivity — | CliffBio